Japanese ophthalmic specialist picks up young private US firm and gains a small but broad set of marketed products.

Meeting to address opioid abuse crisis was also a trial of whether FDA could conduct important public business using online-only technology.

Neither has announced a firm timeline, and the difference between Pfizer's 'October' and Moderna's 'November' could be mere hours or a few weeks, but Pfizer, by dint of luck or experience, is now in a position to offer the more optimistic projection on when it will seek an EUA. Both firms release their Phase III trial protocols, which seem in line with US FDA guidance.